title: Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
abstract: Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants.
authors.affiliation: Clinical Division of Oncology/Department of Medicine I; Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Bartsch
authors.affiliation: Hoffmann-La Roche, Basel, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Frings
authors.affiliation: Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.affiliation: Institut Jules Bordet/Medical Oncology Clinic, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Awada
authors.affiliation: Clinical Division of Oncology/Department of Medicine I; Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
authors.forename: A S
authors.initials: AS
authors.lastname: Berghoff
authors.affiliation: Department of Surgery/Oncology and Gastroenterology, University of Padova, Padova, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Conte
authors.affiliation: Eli-Lilly and Company, Basingstoke, UK.
authors.forename: S
authors.initials: S
authors.lastname: Dickin
authors.affiliation: BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Enzmann
authors.affiliation: Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; Department of Surgery, Medical University of Vienna, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Gnant
authors.affiliation: Roche Diagnostics GmbH, pRED Penzberg, Penzberg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hasmann
authors.affiliation: Hendriks Pharmaceutical Consulting, Purmerend, The Netherlands.
authors.forename: H R
authors.initials: HR
authors.lastname: Hendriks
authors.affiliation: Medical Oncology Department, Arnau Vilanova Hospital, Valencia, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Llombart
authors.affiliation: Novartis, Rueil-Malmaison Cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Massacesi
authors.affiliation: German Breast Group, Neu-Isenburg; University Women's Hospital Frankfurt, Frankfurt, Germany.
authors.forename: G
authors.initials: G
authors.lastname: von Minckwitz
authors.affiliation: Department of Pathology, Centre Jean-Perrin, Clermont-Ferrand; Department of Pathology, University of Auvergne, Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.affiliation: Human Oncology & Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center, New York, USA.
authors.forename: M
authors.initials: M
authors.lastname: Scaltriti
authors.affiliation: Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Yarden
authors.affiliation: Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Zwierzina
authors.affiliation: Clinical Division of Oncology/Department of Medicine I; Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. Electronic address: christoph.zielinski@meduniwien.ac.at.
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D015398:Signal Transduction; D064726:Triple Negative Breast Neoplasms / Q000145:classification / Q000235:genetics / Q000473:pathology* / Q000628:therapy*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: HER2-positive disease; biological subtypes; breast cancer; luminal disease; triple-negative disease